November 2022 Content Release Copied

Clinical Profile Documentation

Problems

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report. Additional ICD-10 codes* may be displayed to present the surrounding nodes. Appendix A contains a complete summary of changes.

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses:

RET gene mutation is now available for Colon cancer, Hepatocellular carcinoma (HCC), and Rectal cancer with the following documentation points:

• RET fusion positive
• RET fusion negative
• Ordered: Result pending
• Not performed
• Unknown

Conventional risk model is now available for Polycythemia vera with the following documentation points:

• Low-risk (age < 60 years and, no history of thrombosis)
• High-risk (age >= 60 years and/or prior history of thrombosis)

MIPSS-PV is now available for Polycythemia vera with the following documentation points:

• Low (0-1 point)
• Intermediate (2-3 points)
• High (4 points or greater)

Updates

FGFR3 gene for Bladder cancer now contains a new documentation point:

• Gene fusion

Polycythemia Vera has been assigned a pathway (PW) designation to ensure documentation remains synonymous with clinical decision support and ICD-10 mapping. The following problems now have PW to the left of the problem in the search results:

• Familial polycythemia vera (disorder)
• Polycythemia vera
• Primary familial polycythemia due to erythropoietin receptor mutation

Lab Analytes & Panels

Additions

• 1-Methylhistidine, umol/L
• 3-Methylhistidine, umol/L
• Adenovirus F40/41 PCR
• Alpha aminoadipate acid, umol/L
• Alpha aminobutyrate acid, umol/L
• AR-V7
• Asparagine, umol/L
• Beta alanine, umol/L
• Beta aminoisobutyrate acid, umol/L
• Blood culture, fungal
• CHD7
• Chlamydia, NAAT, SurePath
• Clostridium difficile tox A/B PCR
• Cystathionine, umol/L
• DLX1
• DPYD activity score
• DPYD disclaimer
• DPYD method
• ERBB2
• ERBB2 (HER2)
• Ethanolamine, umol/L
• Fentanyl+norfentanyl, Ur
• FLT3 ITD allelic ratio
• FLT3 TKD allelic ratio
• FRa, IHC
• Gabapentin/pregabalin, Ur
• Gamma aminobutyrate acid, umol/L
• Ganglioside (Asialo-GM-1) ab, IgG panel
• Ganglioside (Asialo-GM-1) ab, IgM panel
• Ganglioside (GD1a) ab, IgG
• Ganglioside (GD1a) ab, IgG panel
• Ganglioside (GD1a) ab, IgM
• Ganglioside (GD1a) ab, IgM panel
• Ganglioside (GD1b) ab, IgG panel
• Ganglioside (GD1b) ab, IgM panel
• Genital mycoplasmas panel, NAA
• Glutathione, ug/mL
• GSS
• GSTP1
• Guardant360 TissueNext PD-L1
• Guardant360 TissueNext PD-L1 panel
• H. pylori breath test, pediatric
• HOXC6
• HRD
• HRD panel
• HRR
• HRR panel
• Invitae breast cancer guidelines-based panel
• Invitae breast cancer guidelines-based panel result
• Ki67, IHC
• MAP2K1
• MAP2K2
• MMR panel
• Mycoplasma genitalium, NAA
• Mycoplasma hominis, NAA
• PCA3
• PTT-LA baseline
• RASSF1
• RET
• Sarcosine, umol/L
• Serine proteinase 3 Ab, Al
• SPDEF
• Stool pathogen panel by PCR
• Stool pathogen result by PCR
• Tempus xT HRD panel
• Tempus xT MMR panel
• Tempus xT PD-L1 SP142 panel
• Tempus xT PD-L1-22C3 panel
• Tempus xT V4 panel
• Tryptophan, umol/L
• Ureaplasma spp, NAA
• Yersinia enterocolitica PCR

Medications

Additions

• ALG.APV-527 invest IV
• CTX-009 invest IV
• ET0038 invest Oral
• H3B-8800 (RVT-2001) invest Oral

Updates

• JAB-2485 invest Oral
• Relacorilant invest Oral
• SON-1010 invest Subcutaneous

Medication	Update
Brentuximab Vedotin IV	New Instructions: Maximum dose for 1.2 mg/kg is 120 mg and maximum dose for 1.8 mg/kg is 180 mg. Body weight greater than 100 kg should use 100 kg to calculate dose. Administer over 30 mins. Mix in a minimum of 100 mL D5W, NS or LR to achieve a final concentration of 0.4 to 1.8 mg/mL. Do not mix or administer with other drugs.
Eflapegrastim-xnst Subcutaneous	New Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Rolvedon. New Max Single Dose: 13.2 mg New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Futibatinib Oral	New Instructions: Take with or without food. New Max Single Dose: 20 mg New Frequencies: As directed Once
Pegfilgrastim Subcutaneous	New Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Neulasta. New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Pegfilgrastim Subcutaneous (via wearable injector)	New Instructions: May be applied by a healthcare professional on the same day as chemotherapy or the last day of chemotherapy in a multi-day regimen using only the co-packaged pegfilgrastim. Within 3 minutes of filling the on-body reservoir, the device must be applied to patient’s skin (abdomen or back of arm). Usually applied to the abdomen, the back of arm should only be used if there is a caregiver available to monitor the injector. Pegfilgrastim will begin infusing approximately 27 hours later and deliver pegfilgrastim over 45 minutes. NOTE: This is Neulasta On-Body Injector.
Pegfilgrastim-apgf Subcutaneous	New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Pegfilgrastim-bmez Subcutaneous	New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Pegfilgrastim-cbqv Subcutaneous	New Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Udenyca. New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Pegfilgrastim-jmdb Subcutaneous	New Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Fulphila. New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days
Pegfilgrastim-pbbk Subcutaneous	New Instructions: Administer once per cycle at least 24 hours after and 14 days before chemotherapy. NOTE: This is Fylnetra. New Max Single Dose: 6 mg New Frequencies: As directed Every 2 weeks Every 21 days Every 28 days

Regimen Library

Biosimilar and Reference Regimens

To improve ease of ordering, the Collaborative Care Committee (CCC) voted to merge separate biosimilar and reference regimens into single regimen templates. The initiative is complete with this content release.

This release contains the consolidation of all trastuzumab regimen templates and reflects the change in USON preferred product from Kanjinti (Trastuzumab-anns) to Trazimera (Trastuzumab-qyyp).

For a list of all merged trastuzumab regimens please refer to APPENDIX B.

Additions

Regimen Name	Diagnosis
Aspirin Q30D	Polycythemia Vera
Doxorubicin + Cisplatin + Paclitaxel D2 Q21D	Uterine Cancer (Parent)
Efgartigimod alfa-fcab D1,8,15,22 Q50D	Myasthenia Gravis
Fludarabine (25 mg/m2) D1-3 + Cyclophosphamide (250 mg/m2) D1-3 (CAR T-cell Therapy Lymphodepletion)	Lymphoma, Non-Hodgkin (NHL) (Parent)
Fludarabine (30 mg/m2) D1-3 + Cyclophosphamide (300 mg/m2) D1-3 (CAR T-cell Therapy Lymphodepletion)	Lymphoma, Non-Hodgkin (NHL) (Parent)
Fludarabine (30 mg/m2) D1-3 + Cyclophosphamide (500 mg/m2) D1-3 (CAR T-cell Therapy Lymphodepletion)	Lymphoma, Non-Hodgkin (NHL) (Parent)
Futibatinib Q28D	Bile Duct Cancer (Parent)
Nivolumab + Paclitaxel + Cisplatin Q21D (Neoadjuvant NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Tremelimumab-actl + Durvalumab fb Durvalumab Q28D	Hepatocellular Carcinoma (HCC)
Teclistamab-cqyv SQ D1,4,7 (Initial)	Multiple Myeloma (MM)
Teclistamab-cqyv SQ D1,8,15,22 Q28D (Maintenance)	Multiple Myeloma (MM)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

• Breast Cancer
• Colon Cancer
• Esophageal Cancer (Parent)
• Gastric Cancer
• Multiple Myeloma (MM)
• Pancreatic Cancer
• Rectal Cancer
• Uterine Cancer (Parent)

Renames

Previous Name	New Name
Anastrozole Q30D (Ovarian)	Anastrozole Q30D (Ovarian, Uterine)
Cabozantinib (Cabometyx) Q30D (RCC, HCC, Differentiated Thyroid)	Cabozantinib (Cabometyx) Q30D (RCC, HCC, Differentiated Thyroid, Uterine)
Cisplatin Q21D (Endometrial, Cervical, Uterine)	Cisplatin Q21D (Cervical, Uterine)
Docetaxel + Carboplatin Q21D (NSCLC)	Docetaxel + Carboplatin Q21D (NSCLC, Uterine)
Gemcitabine D1,8 + Capecitabine D1-14 Q21D	Gemcitabine D1,8 + Capecitabine (650 mg/m2) D1- 14 Q21D (Bile Duct)
Letrozole Q30D (Ovarian)	Letrozole Q30D (Ovarian, Uterine)
Tamoxifen Q30D (Ovarian)	Tamoxifen Q30D (Ovarian, Uterine)
Selinexor D1,8,15 + Carfilzomib D1,8,15 + Dexamethasone Q28D	Selinexor D1,8,15,22 + Carfilzomib D1,8,15 + Dexamethasone Q28D

Research

Updates

	Updated Reference Information	Updated Drug Service Order Information	Updated Regimen Instructions	Other Changes
USOR 18261	X	X
USOR 20245	X
USOR 20266	X
USOR 20283	X
USOR 20285	X	X	X
USOR 20386	X	X
USOR 20388	X
USOR 20402	X
USOR 20403	X
USOR 21239	X	X	X
USOR 21270	X			Now available: USOR 21270 ZN-c3 (Continuous Dosing) Q21D USOR 21270 ZN-c3 (Intermittent Dosing) Q21D No longer available: USOR 21270 ZN-c3 (PO; Daily) Q21D
USOR 21304	X	X		Now available: USOR 21304 Regimen M Topotecan D1,8,15 + TRK-950 D1,8,15,22 Q28D No longer available: USOR 21304 Ferumoxytol (MRI Contrast Agent) USOR 21304 Regimen K Bevacizumab + TRK-950 D1,8,15 Q21D (Maintenance Phase) USOR 21304 Regimen K Bevacizumab BIOSIMILAR + TRK-950 D1,8,15 Q21D (Maintenance Phase) USOR 21304 Regimen K Gemcitabine D1,8 + Carboplatin + Bevacizumab + TRK-950 D1,8,15 Q21D (Treatment Phase) USOR 21304 Regimen K Gemcitabine D1,8 + Carboplatin + Bevacizumab BIOSIMILAR + TRK-950 D1,8,15 Q21D (Treatment Phase) USOR 21304 Regimen L Bevacizumab + TRK-950 D1,8,15 Q21D (Maintenance Phase) USOR 21304 Regimen L Bevacizumab BIOSIMILAR + TRK-950 D1,8,15 Q21D (Maintenance Phase) USOR 21304 Regimen L Gemcitabine D1,8 + Carboplatin + Bevacizumab + TRK-950 D1,8,15 Q21D (Treatment Phase) USOR 21304 Regimen L Gemcitabine D1,8 + Carboplatin + Bevacizumab BIOSIMILAR + TRK-950 D1,8,15 Q21D (Treatment Phase) USOR 21304 Regimen M Topotecan D1-5 + TRK-950 D1,8,15 Q21D
USOR 21507	X	X
USOR 22041	X	X
USOR 22042		X
USOR 22049	X

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
COVID-19 Vac, BV (Orig,BA4/5) (Moderna) (PF) IM (6 months thru 5 yrs) (Unapproved)	J3590 per 10 mcg 0.2 mL
COVID-19 Vac, BV (Ori,BA4/5) (Pfizer) (PF) IM (6 months thru 4 yrs) (Unapproved)	91302 per 0.3 mL 3 mcg
Indigotindisulfonate (Bludigo)	J3490 per 40 mg 5 mL
Influenza Virus Vaccine Nasal Spray Quad-Split (2 yrs thru 49 yrs) (Flumist)	90672 per 0.2 mL
Insulin Lispro-aabc Continuous Subcutaneous Infusion (Lyumjev)	J3490 per 100 unit/hour
Meningococcal B Vacc, 4-Cmp (PF) (Bexsero)	90620 per 0.5 mL
Meningoc Vac A, C, Y, W-135 Dip (PF) IM (10 to 55 years) (Menveo)	90734 per 0.5 mL
Mening Vac A, C, Y, W-135, Tet (PF) (MenQuadfi)	90619 per 0.5 mL
Pafolacianine (Cytalux)	J3490 per 3.2 mg
Teclistamab-cqyv	J3590 per 30 mg 153 mg
Tremelimumab-actl (Imjudo)	J3590 per 25 mg 300 mg

Appendix A: Problem & Codes Summary

Additions

Problem	ICD-10 Codes
Abnormal findings on diagnostic imaging of lung (finding)	R91.8 Other nonspecific abnormal finding of lung field
Abnormal findings on diagnostic imaging of other specified body structures	R93.89 Abnormal findings on diagnostic imaging of other specified body structures
Accidental poisoning	T43.651A Poisoning by methamphetamines accidental (unintentional), initial encounter T43.651D Poisoning by methamphetamines accidental (unintentional), subsequent encounter T43.651S Poisoning by methamphetamines accidental (unintentional), sequela
Acute appendicitis with gangrene	K35.891 Other acute appendicitis without perforation, with gangrene
Acute deep vein thrombosis of bilateral lower limbs following coronary artery bypass graft (disorder)	I82.403 Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral
Acute deep vein thrombosis of left lower limb following coronary artery bypass graft (disorder)	I82.402 Acute embolism and thrombosis of unspecified deep veins of left lower extremity
Acute deep vein thrombosis of left lower limb following procedure (disorder)	I82.402 Acute embolism and thrombosis of unspecified deep veins of left lower extremity
Acute deep vein thrombosis of lower limb (disorder)	I82.409 Acute embolism and thrombosis of unspecified deep veins of unspecified lower extremity
Acute deep vein thrombosis of right lower limb following coronary artery bypass graft (disorder)	I82.401 Acute embolism and thrombosis of unspecified deep veins of right lower extremity
Acute deep vein thrombosis of right lower limb following procedure (disorder)	I82.401 Acute embolism and thrombosis of unspecified deep veins of right lower extremity
Air leaking from lung (disorder)	J93.82 Other air leak
Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	C84.78 Anaplastic large cell lymphoma, ALK- negative, lymph nodes of multiple sites
Basal cell carcinoma of abdomen (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Basal cell carcinoma of anterior chest (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Basal cell carcinoma of back (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Basal cell carcinoma of chest wall (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Basal cell carcinoma of lower back (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Basal cell carcinoma of truncal skin (disorder)	C44.519 Basal cell carcinoma of skin of other part of trunk
Benign neoplasm of connective and other soft tissue	D21.9 Benign neoplasm of connective and other soft tissue, unspecified
Benign neoplasm of short bones of lower limb	D16.30 Benign neoplasm of short bones of unspecified lower limb D16.31 Benign neoplasm of short bones of right lower limb D16.32 Benign neoplasm of short bones of left lower limb
Benign neoplasm of soft tissue (disorder)	D21.9 Benign neoplasm of connective and other soft tissue, unspecified
Blood chemistry abnormal (finding)	R79.9 Abnormal finding of blood chemistry, unspecified
Body mass index [BMI] 32.0-32.9, adult	Z68.32 Body mass index [BMI] 32.0-32.9, adult
Breast lump (finding)	N63.0 Unspecified lump in unspecified breast
Chronic constipation (disorder)	K59.09 Other constipation
Chronic embolism and thrombosis of unspecified vein	I82.91 Chronic embolism and thrombosis of unspecified vein
Chronic hepatitis C (disorder)	B18.2 Chronic viral hepatitis C
Chronic myeloid leukemia, BCR/ABL-positive in relapse	C92.12 Chronic myeloid leukemia, BCR/ABL- positive in relapse
Chronic myeloid leukemia, BCR/ABL-positive in remission	C92.11 Chronic myeloid leukemia, BCR/ABL- positive in remission
Chronic myeloid leukemia, BCR/ABL-positive not having achieved remission	C92.10 Chronic myeloid leukemia, BCR/ABL- positive not having achieved remission
Chronic salpingo-oophoritis (disorder)	N70.13 Chronic salpingitis and oophoritis
Deficiency of other specified B group vitamins	E53.8 Deficiency of other specified B group vitamins
Dilutional thrombocytopenia (disorder)	D69.59 Other secondary thrombocytopenia
Disorder of pancreas (disorder)	K86.9 Disease of pancreas, unspecified
Disorder of skin (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin and/or subcutaneous tissue (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin AND/OR subcutaneous tissue of flank (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin AND/OR subcutaneous tissue of head (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin AND/OR subcutaneous tissue of neck (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin AND/OR subcutaneous tissue of trunk (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin of head (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin of neck (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Disorder of skin of trunk (disorder)	L98.9 Disorder of the skin and subcutaneous tissue, unspecified
Encounter for preprocedural respiratory examination	Z01.811 Encounter for preprocedural respiratory examination
Enterocolitis due to Clostridium difficile	A04.71 Enterocolitis due to Clostridium difficile, recurrent A04.72 Enterocolitis due to Clostridium difficile, not specified as recurrent
Fibroma (disorder)	D21.9 Benign neoplasm of connective and other soft tissue, unspecified
Flail chest associated with chest compression and cardiopulmonary resuscitation	M96.A4 Flail chest associated with chest compression and cardiopulmonary resuscitation
Fracture of one rib associated with chest compression and cardiopulmonary resuscitation	M96.A2 Fracture of one rib associated with chest compression and cardiopulmonary resuscitation
Fracture of sternum associated with chest compression and cardiopulmonary resuscitation	M96.A1 Fracture of sternum associated with chest compression and cardiopulmonary resuscitation
Hepatoptosis (disorder)	K76.89 Other specified diseases of liver
History of COVID-19	Z86.16 Personal history of COVID-19
Hodgkin’s disease of intrathoracic lymph nodes (disorder)	C81.92 Hodgkin lymphoma, unspecified, intrathoracic lymph nodes
Hydrohepatosis (disorder)	K76.89 Other specified diseases of liver
Idiopathic interstitial pneumonia (disorder)	J84.111 Idiopathic interstitial pneumonia, not otherwise specified
Imaging of lung abnormal (finding)	R91.8 Other nonspecific abnormal finding of lung field
Inflammation of intestine (disorder)	K52.9 Noninfective gastroenteritis and colitis, unspecified
Inflammation of large intestine (disorder)	K52.9 Noninfective gastroenteritis and colitis, unspecified
Insertion of intrauterine contraceptive device (procedure)	Z30.430 Encounter for insertion of intrauterine contraceptive device
Insertion of intrauterine contraceptive device done (situation)	Z30.430 Encounter for insertion of intrauterine contraceptive device
Intentional self poisoning	T43.652A Poisoning by methamphetamines intentional self-harm, initial encounter T43.652D Poisoning by methamphetamines intentional self-harm, subsequent encounter T43.652S Poisoning by methamphetamines intentional self-harm, sequela
Left lower quadrant abdominal swelling, mass and lump	R19.04 Left lower quadrant abdominal swelling, mass and lump
Leiomyoma (disorder)	D21.9 Benign neoplasm of connective and other soft tissue, unspecified
Lobular carcinoma in situ of bilateral breasts (disorder)	D05.01 Lobular carcinoma in situ of right breast D05.02 Lobular carcinoma in situ of left breast
Lobular carcinoma in situ of breast (disorder)	D05.00 Lobular carcinoma in situ of unspecified breast
Lobular carcinoma in situ of left breast (disorder)	D05.02 Lobular carcinoma in situ of left breast
Lobular carcinoma in situ of right breast (disorder)	D05.01 Lobular carcinoma in situ of right breast
Localized swelling of abdominal wall (finding)	R22.2 Localized swelling, mass and lump, trunk
Localized swelling of back (finding)	R22.2 Localized swelling, mass and lump, trunk
Localized swelling of chest wall (finding)	R22.2 Localized swelling, mass and lump, trunk
Localized swelling of head (finding)	R22.2 Localized swelling, mass and lump, trunk
Lung mass (finding)	R91.8 Other nonspecific abnormal finding of lung field
Lymphedema (disorder)	I89.0 Lymphedema, not elsewhere classified
Malignant carcinoid tumor (disorder)	C7A.00 Malignant carcinoid tumor of unspecified site
Malignant carcinoid tumors of other sites	C7A.098 Malignant carcinoid tumors of other sites
Malignant melanoma of buccal mucosa (disorder)	C06.0 Malignant neoplasm of cheek mucosa
Malignant melanoma of auricle (ear) (disorder)	C43.20 Malignant melanoma of unspecified ear and external auricular canal
Malignant melanoma of skin of ankle (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of bilateral lower limbs	C43.71 Malignant melanoma of right lower limb, including hip C43.72 Malignant melanoma of left lower limb, including hip
Malignant melanoma of skin of ear (disorder)	C43.20 Malignant melanoma of unspecified ear and external auricular canal C43.21 Malignant melanoma of right ear and external auricular canal C43.22 Malignant melanoma of left ear and external auricular canal
Malignant melanoma of skin of foot (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of hip (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of knee (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of left ankle (disorder)	C43.72 Malignant melanoma of left lower limb, including hip
Malignant melanoma of skin of left arm (disorder)	C43.62 Malignant melanoma of left upper limb, including shoulder
Malignant melanoma of skin of left ear (disorder)	C43.22 Malignant melanoma of left ear and external auricular canal
Malignant melanoma of skin of left forearm (disorder)	C43.62 Malignant melanoma of left upper limb, including shoulder
Malignant melanoma of skin of left wrist (disorder)	C43.62 Malignant melanoma of left upper limb, including shoulder
Malignant melanoma of skin of lower leg (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of lower limb (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of popliteal area (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of right ankle (disorder)	C43.71 Malignant melanoma of right lower limb, including hip
Malignant melanoma of skin of right ear (disorder)	C43.21 Malignant melanoma of right ear and external auricular canal
Malignant melanoma of skin of right forearm (disorder)	C43.61 Malignant melanoma of right upper limb, including shoulder
Malignant melanoma of skin of right wrist (disorder)	C43.61 Malignant melanoma of right upper limb, including shoulder
Malignant melanoma of skin of thigh (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of toe (disorder)	C43.70 Malignant melanoma of unspecified lower limb, including hip
Malignant melanoma of skin of upper arm (disorder)	C43.61 Malignant melanoma of right upper limb, including shoulder
Malignant melanoma of upper arm (disorder)	C43.60 Malignant melanoma of unspecified upper limb, including shoulder C43.61 Malignant melanoma of right upper limb, including shoulder C43.62 Malignant melanoma of left upper limb, including shoulder
Malignant melanoma of upper limb (disorder)	C43.60 Malignant melanoma of unspecified upper limb, including shoulder C43.61 Malignant melanoma of right upper limb, including shoulder C43.62 Malignant melanoma of left upper limb, including shoulder
Malignant neoplasm of head, face and neck	C76.0 Malignant neoplasm of head, face and neck
Malignant neoplasm of other specified female genital organs	C57.7 Malignant neoplasm of other specified female genital organs
Malignant tumor of buccal mucosa (disorder)	C06.0 Malignant neoplasm of cheek mucosa
Malignant tumor of face (disorder)	C76.0 Malignant neoplasm of head, face and neck
Malignant tumor of head and/or neck (disorder)	C76.0 Malignant neoplasm of head, face and neck
Malignant tumor of neck (disorder)	C76.0 Malignant neoplasm of head, face and neck
Malignant tumor of retromolar area (disorder)	C06.2 Malignant neoplasm of retromolar area
Marginal zone lymphoma of lymph nodes of multiple sites (disorder)	C83.08 Small cell B-cell lymphoma, lymph nodes of multiple sites
Mass of back (finding)	R22.2 Localized swelling, mass and lump, trunk
Mass of chest wall (finding)	R22.2 Localized swelling, mass and lump, trunk
Mass of head (finding)	R22.2 Localized swelling, mass and lump, trunk
Mass of hilum (finding)	R91.8 Other nonspecific abnormal finding of lung field
Mass of male perineum (finding)	R22.2 Localized swelling, mass and lump, trunk
Melanoma in situ of trunk (disorder)	D03.59 Melanoma in situ of other part of trunk
Merkel cell carcinoma of face (disorder)	C4A.30 Merkel cell carcinoma of unspecified part of face C4A.39 Merkel cell carcinoma of other parts of face
Metastasis to peripheral nerve (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Methamphetamine	T43.653A Poisoning by methamphetamines, assault, initial encounter T43.653D Poisoning by methamphetamines, assault, subsequent encounter T43.653S Poisoning by methamphetamines, assault, sequela T43.654A Poisoning by methamphetamines, undetermined, initial encounter T43.654D Poisoning by methamphetamines, undetermined, subsequent encounter T43.654S Poisoning by methamphetamines, undetermined, sequela T43.655A Adverse effect of methamphetamines, initial encounter T43.655D Adverse effect of methamphetamines, subsequent encounter T43.655S Adverse effect of methamphetamines, sequela T43.656A Underdosing of methamphetamines, initial encounter T43.656D Underdosing of methamphetamines, subsequent encounter T43.656S Underdosing of methamphetamines, sequela
Multiple nodules of lung (finding)	R91.8 Other nonspecific abnormal finding of lung field
Multiple fractures of ribs associated with chest compression and cardiopulmonary resuscitation	M96.A3 Multiple fractures of ribs associated with chest compression and cardiopulmonary resuscitation
Myxoma (disorder)	D21.9 Benign neoplasm of connective and other soft tissue, unspecified
Nodule of subcutaneous tissue of abdominal wall (finding)	R22.2 Localized swelling, mass and lump, trunk
Nodule of subcutaneous tissue of back (finding)	R22.2 Localized swelling, mass and lump, trunk
Nodule of subcutaneous tissue of head (finding)	R22.2 Localized swelling, mass and lump, trunk
Non-traumatic acute slipped upper femoral epiphysis, unstable	M93.041 Acute slipped upper femoral epiphysis, unstable (nontraumatic), right hip M93.042 Acute slipped upper femoral epiphysis, unstable (nontraumatic), left hip M93.043 Acute slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip M93.044 Acute slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips
Non-traumatic acute on chronic slipped upper femoral epiphysis, unstable	M93.051 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), right hip M93.052 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), left hip M93.053 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), unspecified hip M93.054 Acute on chronic slipped upper femoral epiphysis, unstable (nontraumatic), bilateral hips
Other abnormal findings in specimens from respiratory organs and thorax	R84.8 Other abnormal findings in specimens from respiratory organs and thorax
Other acute appendicitis without perforation, with gangrene	K35.891 Other acute appendicitis without perforation, with gangrene
Other acute pancreatitis with infected necrosis	K85.82 Other acute pancreatitis with infected necrosis
Other acute pancreatitis with uninfected necrosis	K85.81 Other acute pancreatitis with uninfected necrosis
Other acute pancreatitis without necrosis or infection	K85.80 Other acute pancreatitis without necrosis or infection
Other and unspecified ventral hernia with obstruction, without gangrene	K43.6 Other and unspecified ventral hernia with obstruction, without gangrene
Other appendicitis	K36 Other appendicitis
Other congenital malformations of breast	Q83.8 Other congenital malformations of breast
Other congenital malformations of uterus	Q51.818 Other congenital malformations of uterus
Other constipation	K59.09 Other constipation
Other diseases of stomach and duodenum	K31.89 Other diseases of stomach and duodenum
Other Hodgkin lymphoma, lymph nodes of multiple sites	C81.78 Other Hodgkin lymphoma, lymph nodes of multiple sites
Other intestinal obstruction unspecified as to partial versus complete obstruction	K56.699 Other intestinal obstruction unspecified as to partial versus complete obstruction
Other lymphoid leukemia in relapse	C91.Z2 Other lymphoid leukemia in relapse
Other lymphoid leukemia in remission	C91.Z1 Other lymphoid leukemia in remission
Other lymphoid leukemia not having achieved remission	C91.Z0 Other lymphoid leukemia not having achieved remission
Other neutropenia	D70.8 Other neutropenia
Other noninflammatory disorders of ovary, fallopian tube and broad ligament	N83.8 Other noninflammatory disorders of ovary, fallopian tube and broad ligament
Other nonspecific abnormal finding of lung field	R91.8 Other nonspecific abnormal finding of lung field
Other postprocedural complications and disorders of digestive system	K91.89 Other postprocedural complications and disorders of digestive system
Other secondary thrombocytopenia	D69.59 Other secondary thrombocytopenia
Other specified bacterial agents as the cause of diseases classified elsewhere	B96.89 Other specified bacterial agents as the cause of diseases classified elsewhere
Other specified bacterial intestinal infections	A04.8 Other specified bacterial intestinal infections
Other specified diseases of appendix	K38.8 Other specified diseases of appendix
Other specified diseases of liver	K76.89 Other specified diseases of liver
Other specified disorders of bone density and structure, unspecified site	M85.80 Other specified disorders of bone density and structure, unspecified site
Other specified disorders of bladder	N32.89 Other specified disorders of bladder
Other specified malignant neoplasm of skin, unspecified	C44.99 Other specified malignant neoplasm of skin, unspecified
Other specified noninfective gastroenteritis and colitis	K52.89 Other specified noninfective gastroenteritis and colitis
Other specified soft tissue disorders	M79.89 Other specified soft tissue disorders
Other ventricular tachycardia	I47.29 Other ventricular tachycardia
Other vitamin B12 deficiency anemias	D51.8 Other vitamin B12 deficiency anemias
Other ulcerative colitis with unspecified complications	K51.819 Other ulcerative colitis with unspecified complications
Overlapping malignant neoplasm of vulva (disorder)	C51.8 Malignant neoplasm of overlapping sites of vulva
Patient’s noncompliance with dietary regimen due to financial hardship	Z91.110 Patient’s noncompliance with dietary regimen due to financial hardship
Patient’s noncompliance with dietary regimen due to unspecified reason	Z91.119 Patient’s noncompliance with dietary regimen due to unspecified reason
Patient’s noncompliance with dietary regimen for other reason	Z91.118 Patient’s noncompliance with dietary regimen for other reason
Patient’s noncompliance with other medical treatment and regimen due to unspecified reason	Z91.199 Patient’s noncompliance with other medical treatment and regimen due to unspecified reason
Patient’s noncompliance with other medical treatment and regimen for other reason	Z91.198 Patient’s noncompliance with other medical treatment and regimen for other reason
Polyalgia (disorder)	M79.89 Other specified soft tissue disorders
Postprocedural seroma of skin and subcutaneous tissue following other procedure	L76.34 Postprocedural seroma of skin and subcutaneous tissue following other procedure
Primary malignant neoplasm of bilateral kidneys (disorder)	C64.1 Malignant neoplasm of right kidney, except renal pelvis C64.2 Malignant neoplasm of left kidney, except renal pelvis
Primary malignant neoplasm of buccal mucosa (disorder)	C06.0 Malignant neoplasm of cheek mucosa
Primary malignant neoplasm of face (disorder)	C76.0 Malignant neoplasm of head, face and neck
Primary malignant neoplasm of gastrointestinal tract (disorder)	C26.9 Malignant neoplasm of ill-defined sites within the digestive system
Primary malignant neoplasm of head (disorder)	C76.0 Malignant neoplasm of head, face and neck
Primary malignant neoplasm of neck (disorder)	C76.0 Malignant neoplasm of head, face and neck
Primary malignant neoplasm of nose (disorder)	C76.0 Malignant neoplasm of head, face and neck
Primary malignant neoplasm of retromolar area (disorder)	C06.2 Malignant neoplasm of retromolar area
Primary renal cell carcinoma of left kidney (disorder)	C64.2 Malignant neoplasm of left kidney, except renal pelvis
Primary renal cell carcinoma of right kidney (disorder)	C64.1 Malignant neoplasm of right kidney, except renal pelvis
Primary squamous cell carcinoma of skin of left hand (disorder)	C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Primary squamous cell carcinoma of skin of left shoulder (disorder)	C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Primary squamous cell carcinoma of skin of left upper limb (disorder)	C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Primary squamous cell carcinoma of skin of right hand (disorder)	C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder
Primary squamous cell carcinoma of skin of right shoulder (disorder)	C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder
Primary squamous cell carcinoma of skin of right upper limb (disorder)	C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder
Primary squamous cell carcinoma of upper limb (disorder)	C44.621 Squamous cell carcinoma of skin of unspecified upper limb, including shoulder C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Right lower quadrant abdominal swelling, mass and lump	R19.03 Right lower quadrant abdominal swelling, mass and lump
Secondary malignant neoplasm of blood vessel (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of chest wall (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of heart (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of lymph nodes from thyroid (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of mouth (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of muscle (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of other parts of nervous system	C79.49 Secondary malignant neoplasm of other parts of nervous system
Secondary malignant neoplasm of parotid gland (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of soft tissues of axilla (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of soft tissues of buttock (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of soft tissues of neck (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of soft tissues of pelvis (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Secondary malignant neoplasm of thyroid gland (disorder)	C79.89 Secondary malignant neoplasm of other specified sites
Shadow of lung (finding)	R91.8 Other nonspecific abnormal finding of lung field
Small lymphocytic B-cell lymphoma of lymph nodes of multiple sites (disorder)	C83.08 Small cell B-cell lymphoma, lymph nodes of multiple sites
Soft tissue infection (disorder)	M79.89 Other specified soft tissue disorders
Squamous cell carcinoma of buccal mucosa (disorder)	C06.0 Malignant neoplasm of cheek mucosa
Squamous cell carcinoma of hand (disorder)	C44.621 Squamous cell carcinoma of skin of unspecified upper limb, including shoulder C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulderC44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Squamous cell carcinoma of upper extremity (disorder)	C44.621 Squamous cell carcinoma of skin of unspecified upper limb, including shoulder C44.622 Squamous cell carcinoma of skin of right upper limb, including shoulder C44.629 Squamous cell carcinoma of skin of left upper limb, including shoulder
Standard chest X-ray abnormal (finding)	R91.8 Other nonspecific abnormal finding of lung field
Subcutaneous nodular fat necrosis in pancreatitis (disorder)	M79.89 Other specified soft tissue disorders
Superficial endometriosis of ureter	N80.A41 Superficial endometriosis of right ureter N80.A42 Superficial endometriosis of left ureter N80.A43 Superficial endometriosis of bilateral ureters N80.A49 Superficial endometriosis of unspecified ureter
Swelling of finger (finding)	M79.89 Other specified soft tissue disorders
Swelling of finger joint (finding)	M79.89 Other specified soft tissue disorders
Swelling of finger of left hand (finding)	M79.89 Other specified soft tissue disorders
Swelling of finger of right hand (finding)	M79.89 Other specified soft tissue disorders
Swelling of left lower limb (finding)	M79.89 Other specified soft tissue disorders
Swelling of right lower limb (finding)	M79.89 Other specified soft tissue disorders
Thrombocytopenia caused by alcohol (disorder)	D69.59 Other secondary thrombocytopenia
Thrombocytopenia caused by drugs (disorder)	D69.59 Other secondary thrombocytopenia
Thrombocytopenia due to extracorporeal circulation (disorder)	D69.59 Other secondary thrombocytopenia
Thrombocytopenia due to extracorporeal circulation of blood (disorder)	D69.59 Other secondary thrombocytopenia
Thrombocytopenia due to massive blood transfusion (disorder)	D69.59 Other secondary thrombocytopenia
Unspecified condition associated with female genital organs and menstrual cycle	N94.9 Unspecified condition associated with female genital organs and menstrual cycle
Unspecified malignant neoplasm of anal skin	C44.500 Unspecified malignant neoplasm of anal skin

Appendix B: Regimen Consolidation Summary

Additions

The following regimens have been created as part of the Reference Regimen / Biosimilar Merge initiative.

• Anastrozole + Trastuzumab IV Q21D
• Capecitabine D1-14 + Cisplatin + Trastuzumab IV + Pembrolizumab Q21D
• Capecitabine D1-14 + Cisplatin + Trastuzumab IV Q21D
• Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV + Pembrolizumab Q21D
• Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV Q21D
• Capecitabine D1-14 + Trastuzumab IV Q21D
• Docetaxel + Carboplatin + Trastuzumab IV (TCH) + Pertuzumab IV Q21D
• Docetaxel + Carboplatin + Trastuzumab IV (TCH) Q21D
• Docetaxel + Cyclophosphamide + Trastuzumab IV Q21D
• Docetaxel + Trastuzumab IV Q21D
• Docetaxel D1,8,15 + Trastuzumab IV D1,8,15 Q28D
• Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense fb Paclitaxel + Trastuzumab IV D1,8 Q14D (Part 1 of 2- AC fb Paclitaxel + Trastuzumab IV)
• Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense fb Paclitaxel + Trastuzumab IV D1,8 Q14D (Part 2 of 2: Trastuzumab IV Maintenance)
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Pertuzumab IV + Trastuzumab IV Q21D
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Trastuzumab IV Q21D
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel + Trastuzumab IV Q21D
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel D1,8,15 + Pertuzumab IV + Trastuzumab IV Q21D
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel Weekly D1,8,15 + Trastuzumab IV Weekly D1,8,15 Q21D
• Eribulin D1,8 + Trastuzumab IV Q21D
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Trastuzumab IV Q14D
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Trastuzumab IV Q14D
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Trastuzumab IV Q14D + Pembrolizumab Q42D
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) (Q14D) + Trastuzumab IV + Pembrolizumab (Q21D) Q42D
• Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV + Pembrolizumab Q21D
• Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV Q21D
• Ixabepilone + Trastuzumab IV Q21D
• Lapatinib + Trastuzumab IV D1,8,15 Q21D
• Lapatinib + Trastuzumab IV Q21D
• Letrozole + Trastuzumab IV Q21D
• Paclitaxel + Carboplatin + Trastuzumab IV D1,8,15,22,29,36 Q56D
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Esophageal, Gastric)
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Part 1 of 2, Uterine)
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Part 2 of 2: Trastuzumab Only, Uterine)
• Paclitaxel + Trastuzumab IV Q21D (Metastatic)
• Paclitaxel D1,8,15 + Trastuzumab IV + Pertuzumab IV Q21D (Neoadjuvant)
• Paclitaxel D1,8,15 + Trastuzumab IV D1,8,15 Q21D (Adjuvant)
• Paclitaxel D1,8,15 + Trastuzumab IV D1,8,15 Q21D (Metastatic)
• Pertuzumab IV + Trastuzumab IV + Docetaxel Q21D
• Pertuzumab IV + Trastuzumab IV + Paclitaxel D1,8,15 Q21D (Metastatic)
• Pertuzumab IV + Trastuzumab IV Q21D (Colon, Rectal, Bile Duct)
• Pertuzumab IV + Trastuzumab IV Q21D (following Pertuzumab + Trastuzumab + Taxane regimens)
• Pertuzumab IV + Trastuzumab IV Q21D Maintenance (following non-TCH regimens)
• Pertuzumab IV + Trastuzumab IV Q21D Maintenance (following TCH + Pertuzumab regimens)
• Trastuzumab IV Q21D Maintenance (following non-TCH regimens)
• Trastuzumab IV Q21D Maintenance (following TCH regimens)
• Trastuzumab IV Weekly Maintenance
• Tucatinib + Capecitabine D1-14 + Trastuzumab IV Q21D
• Vinorelbine D1,8,15 + Trastuzumab IV D1,8,15 Q21D

Removals

The following regimens have been inactivated as part of the Reference Regimen / Biosimilar Merge initiative:

• Anastrozole + Trastuzumab IV Q21D Reference
• Capecitabine D1-14 + Cisplatin + Trastuzumab IV + Pembrolizumab Q21D Reference
• Capecitabine D1-14 + Cisplatin + Trastuzumab IV Q21D Reference
• Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV + Pembrolizumab Q21D Reference
• Capecitabine D1-14 + Oxaliplatin (XELOX/CAPOX) + Trastuzumab IV Q21D Reference
• Capecitabine D1-14 + Trastuzumab IV Q21D Reference
• Docetaxel + Carboplatin + Trastuzumab IV (TCH) + Pertuzumab IV Q21D Reference
• Docetaxel + Carboplatin + Trastuzumab IV (TCH) Q21D Reference
• Docetaxel + Cyclophosphamide + Trastuzumab IV Q21D Reference
• Docetaxel + Trastuzumab IV Q21D Reference
• Docetaxel D1,8,15 + Trastuzumab IV D1,8,15 Q28D Reference
• Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense fb Paclitaxel + Trastuzumab IV D1,8 Q14D (Part 1 of 2: AC fb Paclitaxel + Trastuzumab IV) Reference
• Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense fb Paclitaxel + Trastuzumab IV D1,8 Q14D (Part 2 of 2: Trastuzumab IV Maintenance) Reference
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Pertuzumab IV + Trastuzumab IV Q21D Reference
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Docetaxel + Trastuzumab IV Q21D Reference
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel + Trastuzumab IV Q21D Reference
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel D1,8,15 + Pertuzumab IV + Trastuzumab IV Q21D Reference
• Doxorubicin + Cyclophosphamide (AC) Q21D fb Paclitaxel Weekly D1,8,15 + Trastuzumab IV Weekly D1,8,15 Q21D Reference
• Eribulin D1,8 + Trastuzumab IV Q21D Reference
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Irinotecan (FOLFIRI) + Trastuzumab IV Q14D Reference
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) (Q14D) + Trastuzumab IV + Pembrolizumab (Q21D) Q42D Reference
• Fluorouracil (Bolus + CIV) D1-2 + Leucovorin + Oxaliplatin (FOLFOX 6, Modified) + Trastuzumab IV Q14D Reference
• Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV + Pembrolizumab Q21D Reference
• Fluorouracil CIV D1-5 + Cisplatin + Trastuzumab IV Q21D Reference
• Ixabepilone + Trastuzumab IV Q21D Reference
• Lapatinib + Trastuzumab IV D1,8,15 Q21D Reference
• Lapatinib + Trastuzumab IV Q21D Reference
• Letrozole + Trastuzumab IV Q21D Reference
• Paclitaxel + Carboplatin + Trastuzumab IV D1,8,15,22,29,36 Q56D Reference
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Breast) Reference
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Esophageal, Gastric) Reference
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Part 1 of 2, Uterine) Reference
• Paclitaxel + Carboplatin + Trastuzumab IV Q21D (Part 2 of 2: Trastuzumab Only, Uterine) Reference
• Paclitaxel + Trastuzumab IV Q21D (Metastatic) Reference
• Paclitaxel D1,8,15 + Trastuzumab IV + Pertuzumab IV Q21D (Neoadjuvant) Reference
• Paclitaxel D1,8,15 + Trastuzumab IV D1,8,15 Q21D (Adjuvant) Reference
• Paclitaxel D1,8,15 + Trastuzumab IV D1,8,15 Q21D (Metastatic) Reference
• Pertuzumab IV + Trastuzumab IV + Docetaxel Q21D Reference
• Pertuzumab IV + Trastuzumab IV + Paclitaxel D1,8,15 Q21D Reference
• Pertuzumab IV + Trastuzumab IV Q21D (following Pertuzumab + Trastuzumab + Taxane regimens) Reference
• Trastuzumab IV + Pertuzumab IV Q21D Maintenance (following non-TCH regimens) Reference
• Trastuzumab IV + Pertuzumab IV Q21D Maintenance (following TCH + Pertuzumab regimens) Reference
• Trastuzumab IV Q21D Maintenance (following non-TCH regimens) Reference
• Trastuzumab IV Q21D Maintenance (following TCH regimens) Reference
• Trastuzumab IV Weekly Maintenance Reference
• Tucatinib + Capecitabine D1-14 + Trastuzumab IV Q21D Reference
• Vinorelbine D1,8,15 + Trastuzumab IV D1,8,15 Q21D Reference